Welcome to our dedicated page for Tactile Systems news (Ticker: TCMD), a resource for investors and traders seeking the latest updates and insights on Tactile Systems stock.
Tactile Systems Technology Inc (NASDAQ: TCMD) delivers innovative medical solutions for chronic conditions through advanced home therapy devices. This news hub provides investors and healthcare professionals with essential updates on corporate developments, clinical advancements, and regulatory milestones.
Track key updates including quarterly earnings reports, new product clearances, partnership announcements, and clinical study results. Our curated collection ensures access to verified press releases and objective market analysis related to lymphedema management and venous insufficiency treatments.
Discover comprehensive coverage of TCMD's operational progress, including FDA submissions, insurance reimbursement developments, and technological innovations in pneumatic compression therapy. All content is maintained to meet strict journalistic standards for accuracy and relevance in the medical device sector.
Bookmark this page for streamlined access to Tactile Systems' latest announcements and historical performance data. Check regularly for updates that could impact understanding of the company's market position in home-based chronic care solutions.
Tactile Systems Technology (TCMD) reported strong Q2 2024 financial results, with total revenue increasing 7% year-over-year to $73.2 million. Lymphedema product revenue grew 8%, while airway clearance product revenue rose 2%. The company achieved net income of $4.3 million, compared to a net loss in Q2 2023, and Adjusted EBITDA increased 49% to $9.1 million.
Key highlights include:
- Gross margin improved to 73.9% of revenue
- Operating income reached $5.8 million
- 510(k) clearance obtained for Nimbl system, a next-generation lymphedema therapy platform
- Sheri Dodd appointed as new President and CEO
Tactile Medical updated its 2024 financial outlook, now expecting full-year revenue between $293 million and $298 million, representing 7-9% growth year-over-year.
Tactile Systems Technology, Inc. (Nasdaq: TCMD), operating as Tactile Medical, has announced the release date for its second quarter fiscal year 2024 financial results. The results will be disclosed after market close on Monday, August 5, 2024. Following the release, management will host a conference call with a Q&A session at 5:00 p.m. Eastern Time on the same day.
Interested parties can participate in the call by dialing 877-407-3088 (201-389-0927 for international callers) and using the access code 13745955. A live webcast will be available on the company's investor relations website. For those unable to attend, a replay will be accessible for two weeks.
Tactile Medical, symbol TCMD on Nasdaq, announced its participation at the William Blair 44th Annual Growth Stock Conference, taking place from June 4-6, 2024, at the Loews Hotel in Chicago, IL. Management will engage in a fireside chat on June 4 at 9:20 a.m. CT, with a live audio webcast available on the company's investor relations website. The webcast will also be archived for later access. Tactile Medical specializes in at-home therapies for chronic conditions like lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease. The company aims to improve patient outcomes by working with clinicians to expand evidence and awareness, enhance care access, reduce healthcare costs, and improve quality of life.
Tactile Systems Technology, Inc. reported a 4% increase in total revenue to $61.1 million for Q1 2024. The company's lymphedema product revenue grew 5% while airway clearance product revenue decreased by 4%. Net loss was $2.2 million versus $1.9 million in Q1 2023. Adjusted EBITDA rose to $1.0 million from $0.5 million in Q1 2023. The company also completed a clinical trial and published a peer-reviewed study on its products.
FAQ
What is the current stock price of Tactile Systems (TCMD)?
What is the market cap of Tactile Systems (TCMD)?
